To evaluate retrospectively the ef®cacy of adjuvant radiation therapy (ART) in patients with T1 ± T2 prostate cancer (CaP) in whom extracapsular cancer (pT3) was detected after radical prostatectomy (RP), together with biochemical failure characterized by a recurrent level of serum prostate-speci®c antigen (PSA) b 0.1 ngamL.
Introduction
Detectable serum levels of prostate-speci®c antigen (PSA) 1 month after radical prostatectomy (RP) indicate residualarecurrent disease. External beam radiation therapy is therefore most often applied if local recurrence is suspected. However, the modalities of adjuvant radiation therapy (ART) after RP are still debated. Should it be initiated immediately, where pT3 disease is noted in the pathology report, or should it be delayed until PSA recurs? Furthermore, it is dif®cult to pinpoint which patients, among those who show such a recurrence, actually need adjuvant treatment and therefore are more likely to bene®t from ART.
At our institution, ART is offered to pT3 patients who have elevated levels of serum PSA after RP, but no other evidence of metastatic disease. We report here the results of ART in 22 patients with pT3 cancer and detectable postoperative PSA.
Materials and methods
Between September 1988 and September 1996, 215 RP operations were performed at our hospital, for clinically localized prostate cancer. Of these patients, 22 had ART for persistentarecurrent PSA with no evidence of distant metastasis and were studied retrospectively. All had pT3 disease noted in the initial pathology report.
The mean preoperative serum PSA (modi®ed polyclonal Yang assay) was 17.9 (4.5 ± 35) ngamL. Postoperative PSA levels were measured using an ultrasensitive (Yang modi®ed) assay with a detection threshold of 0.1 ngamL. Postoperative biochemical failure was de®ned as a persistentarecurrent postoperative PSA level in excess of 0.1 ngamL. Low preoperative PSA level was arbitrarily de®ned as less than 10 ngamL.
RP specimens were processed according to the Stanford method and positive surgical margins were de®ned as the presence of carcinoma at the linked limits of the specimen, suggesting that removal had been incomplete. A total of 15 patients underwent transrectal ultrasound-guided biopsy of the anastomosis (resection site).
Patients underwent boneaCT scanning and chest radiography before ART; normal ®ndings with these procedures were a prerequisite for ART.
A total dose of 65 Gy was delivered to the prostatic bed (the area from which the prostate had been removed), in fractions each of 2.25 Gy, four fractions per week (9 Gyaweek). All the patients were treated using a four®elds box technique and using a 18 MV photons linear accelerator. No conformal radiation therapy was done. The pelvic lymph nodes were not included in the initial ®elds. The mean interval between RP and ART was 25.6 (6 ± 72) months.
After ART, PSA was determined at least once every six months with a mean follow-up of 32.5 (6 ± 60) months. After ART, two groups of patients were de®ned, according to the biochemical results: group I comprised those patients in whom PSA was undetectable on one or more occasions after completion of ART; Patients in group II showed only a partial decrease, if any, in serum PSA level after completion of ART.
It was postulated that post-ART biological failure, was due to either metastasis undetectable prior to radiotherapy or to local tumoral recurrence. However, no further conventional radiology exam was performed since the volume of distantalocal tumoral recurrence is at this time so small that radiology would not make a worthwhile contribution to the diagnosis and to the therapeutic strategy either.
Preoperative PSA, pathology features (Gleason score, positive surgical margins, invasion of seminal vesicles), PSA doubling time, timing of ART, serum PSA level prior to ART, and the results of biopsy of the resection site (anastomosis), were recorded and compared with the biochemical results after ART.
Urinary and rectal morbidity were graded in accordance with Radiation Therapy Oncology Group (RTOG) guidelines.
The chi-squared test was used to evaluate statistical differences between groups (with correction for low numbers) and the Wilcoxon nonparametric test was used for comparison of means.
Results
The tolerance of the treatment was usually good. We noted, according to RTOG morbidity grading system, grade 1 or 2 side effects (urgency, proctitis, diarrhea) in nine patients (40.9%). One patient only experienced a grade 3 complication. These symptoms were always transient and disappeared between 1 and 6 months after ART.
In this series, nine patients had positive seminal vesicles and 13 had positive surgical margins (8 out of 14 in group I: patients with post-ART undetectable PSA; 5 out of 8 in group II: patients with uncomplete post-ART PSA response). The mean preoperative PSA was 10.7 (6.2 ± 16) ngamL in group I and 19.3 (4.5 ± 35) ngamL in group II (P`0.05). The mean PSA prior to ART was 1.1 (0.14 ± 2.5) ngamL in group I and 2.9 (0.3 ± 7.2) ngamL in group II.
In 19 patients (19 out of 22, 86.4%) a decrease in serum PSA levels was noted; in 14 of these (14 out of 22, 63.6%; group I) a complete biochemical response (de®ned as an undetectable PSA level at any time (that is, on one or more occasions) after completion of ART) was achieved, in 12 patients this being noted within three months of the completion of ART. In eight patients (8 out of 22, 36.4%) this complete biochemical response was durable (persistent) over a mean follow-up period of 20.4 (9 ± 48) months and in one patient a durable but incomplete response (0.15 ngamL at 12 months) was noted (Table 1) .
Nevertheless, as shown in Figure 1 , the percentage of patients with an undetectable level of PSA after ART showed a continual decrease with increasing length of follow-up.
Of the eight patients who, prior to ART, had serum PSA levels lower than 1 ngamL, a complete biochemical response was noted in seven, and this was durable in 6. In all seven, PSA was undetectable one month after ART.
The only two factors found to have a statistically signi®cant correlation with complete biochemical response to ART were low preoperative PSA and low PSA prior to ART (Table 2) .
No difference in biochemical response after ART was observed between patients with recurrent elevated postoperative PSA and those with persistently elevated postoperative PSA.
Discussion
It has been postulated that biochemical failure (recurrence of serum PSA b 0.1 ngamL) after RP may be attributable to local residualarecurrent disease, where resection site biopsy is positive in conjunction with low PSA doubling time and no other evidence of distant metastasis. CT scan and bone scan must be performed prior to ART for tumor widespread assessment; however, most often they are negative since tumor volume is very low at this time.
Previously reported rates of response to ART have varied widely.
1 ± 3 These differences may re¯ect differences in response de®nition, patient selection, time of follow-up, and PSA detection threshold, making it dif®cult to compare results between studies. However, in considering the most recent series, 4 ± 6 of studies that focus on the biochemical response obtained in pT3 patients, the proportion of patients who are free of disease as de®ned according to biochemical criteria is constantly less than that of patients clinically free of disease.
In our series, the rate of durable complete biochemical response is low (36.4%) at a mean follow-up of 20.4 months, whereas previously published rates of pT2apT3 patients with undetectable PSA at last follow-up range from 50 ± 59%.
7 ± 10 These con¯icting results are explained by the use, in our study, of an ultrasensitive PSA assay (detection threshold 0.1 ngamL) which enables biochemical failure to be detected at an earlier stage than in other series, despite a shorter follow-up period.
We have noted a more durable response to ART if PSA prior to ART is 1 ngamL or lower. Schild et al 11 reported similar results. These ®ndings probably re¯ect a lesser degree of residual disease in these patients, before ART.
Link et al 7 underlined the poor results of radiation therapy in post-radical prostatectomy patients whose PSA does not decrease to undetectable levels after surgery. Their dates suggested that the lower the PSA prior to ART, the better the results. This opinion is widely shared in literature. 8, 9 Preoperative PSA also appears to be predictive of good results after ART, possibly because, in the context of patients who show biochemical progression after RP, high levels of PSA re¯ect micrometastatic disease at the time of surgery. Indeed, if ART fails to cure a patient it is either because local residualarecurrent tumor is too bulky or because metastasis has already occurred.
With regard to the postoperative PSA velocity, most authors 6,9,10 have underlined the fact that an increasing PSA level of 0.75 ngamL per year is related to metastatic disease in over 50% of cases, and that these patients are probably not the best target for ART. In our series we have not noted any correlation between postoperative PSA velocity and response to ART, probably because the calculation of PSA velocity depends on PSA sampling and, in this retrospective study, PSA has not necessarily been sampled at the same time for every patient.
We previously reported signi®cantly worse results in patients with seminal vesicle involvement. However, with Group I patients in whom PSA was undetectable on at least one occasion after ART; Group II patients in whom only a partial (or no) decrease in PSA was noted after ART. a Detectable but low durable PSA result (0.15 ng/mL at 12 months); NBA needle biopsy of anastomosis; RP radical prostatectomy; ART adjuvant radiation therapy; ND not done; positive; Ð negative.
further follow-up we have been unable to reproduce this ®nding. Schild et al 11 reported similar data. Most previous reports 1,4,12 have noted that an undoubted advantage is conferred by surgery plus ART over surgery alone, with regard to speci®c survival rate, metastasis-free disease, and local recurrence. However, Freeman et al 13 found no difference in local recurrence when comparing both treatments. The extreme heterogeneity of these studies does not make any comparison easy. It would be interesting to compare the results of surgery alone vs surgery plus ART in randomized pT3 patients with positiveanegative surgical margins. Therefore, although our results do not support the use of ART in patients with detectable PSA after RP, they indicate that, where ART is, nevertheless, resorted to, it is better to administer it when serum PSA is still less than 1 ngamL.
The occurrence of rising postoperative PSA is related to tumor recurrence. Therefore, a curative dose (60 ± 70 Gy) must be recommended to treat these patients rather than a prophylactic dose (45 Gy). This attitude is followed by most of the authors using postoperative radiation therapy in case of pT3. 13, 14 In the opinion of Forman, 15 ART may have better results if the total dose delivered to the prostate bed is up to 74 Gy; however, the use of conformal radiation techniques are mandatory if a dose higher than 70 Gy is delivered.
It has been suggested that positive biopsy of the resection site (anastomosis) re¯ects recurrentaresidual disease, rather than metastatic disease that ART cannot be expected to eradicate. In our series, only a few patients have undergone such a biopsy; however, in this setting, the number of positive biopsies was found to be even higher in the group of patients showing an incomplete biochemical response. It is not known, therefore, whether this ®nding is due to random distribution or whether it is because a complete biochemical response is achieved chie¯y in cases of low-volume tumors, in which there is some dif®culty in obtaining a biopsy specimen of cancerous tissue from the anastomatic area prior to ART.
Conclusions
The results of our series indicate that a short interval between RP and ART is not predictive of a good biochemical result. These ®ndings are similar to those of Partin, 10 but do not corroborate those of others. 11, 16 A persistently elevated postoperative PSA has been described 5,7,12 as predictive of an unfavourable response to ART, but, again, we did not ®nd such a correlation. These con¯icting reports are probably explicable in terms of the wide variations in response de®nitions and patient settings in these different series.
In this group of high risk pT3 patients, ART for biochemical failure after RP may lead to undetectable PSA levels in a signi®cant (63.6%) proportion of patients, however a longer follow-up shows that such unmeasurable levels persist in roughly one third of such patients. Since 20 ± 30% of pT3 patients do not experience any postoperative rising PSA at time of last follow-up, and would be irradiated for nothing, we strongly recommend that only those patients who are most likely to bene®t from ART are selected. In our experience, such patients are those with low preoperative PSA, and with serum PSA prior to ART of less than 1 ngamL. 
